Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial.

Francesco Passiglia Luisella Righi Paolo Bironzo Angela Listì Giovanni Farinea Enrica Capelletto Silvia Novello Alessandra Merlini Giorgio Vittorio Scagliotti

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

This preliminary analysis highlighted the lack of antitumor activity for the combination of niraparib and dostarlimab in patients with PM and/or advanced NSCLC harboring BAP1 somatic mutations. A potential antitumor activity emerged for PM with germline BAP1 and/or BRCA2 somatic mutations along with a good tolerability profile.

Keyphrases

particulate matter
air pollution
small cell lung cancer
heavy metals
copy number
clinical trial
study protocol
open label
randomized controlled trial
water soluble
gene expression
dna repair
risk assessment
climate change
brain metastases